The acquisition of resistance via Lyn correlates with decreased expression of BCR-ABL, as has been shown in Bcr-Abl-positive CML cells cultured in the continuous presence of imatinib [32]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.